Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
REGENXBIO outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases
REGENXBIO has announced key milestones for 2026 across its therapeutic programs for Duchenne muscular dystrophy, wet AMD, and diabetic retinopathy. The company is actively working towards releasing pivotal trial data for these indications. This strategic outline highlights REGENXBIO’s focus on advancing its gene therapies and bringing them closer to market.